Amyris to acquire sweet protein developer Oobli

Amyris, a vertically integrated biomanufacturing company, plans to acquire sweet protein developer Oobli. 

Oobli makes sweet proteins through fermentation. These proteins occur naturally in rare fruits and berries that grow near the equator. The company describes its products as the first of their kind in the sugar reduction category.

According to the companies, sweet proteins are hundreds to thousands of times sweeter than sugar. They bind directly to sweet taste receptors. The body metabolizes them as protein, so they do not cause blood sugar spikes or gut disruption.

Oobli’s portfolio includes Oubli fruit, serendipity berry and katemfe fruit sweet proteins. Their scientific names are brazzein, monellin and thaumatin. The portfolio has FDA GRAS status as an ingredient. It is also FEMA GRAS-affirmed for use as a natural flavor.

- Advertisement -
Ad imageAd image

Amyris brings strain engineering, biomanufacturing scale and commercial reach. It expanded capacity earlier this year at its fermentation facility in Barra Bonita, Brazil. The company says the acquisition extends its presence in protein and peptide-based solutions.

Oobli’s sweet proteins will be the first to use the combined platform. They can serve categories including sports nutrition, dairy, beverages, chocolate, bakery and confectionery.

Amyris CEO Kathy Fortmann said the two platforms complement each other. She said Amyris can bring commercial scale to speed up Oobli’s growth. She also said the pairing could widen Amyris’ reach beyond food and beverage, into personal care, flavors and fragrances, and agriculture.

Oobli CEO Ali Wing said joining Amyris gives the company the scale and resources to make sweet proteins a global standard in sweetness solutions.

Amyris said existing customer commitments and brand partnerships will continue without interruption.

Share This Article